A retrospective translational study: Characterisation of molecular predictors of outcome in patients with diffuse large B cell lymphoma treated on the R-CHOP14 vs 21 multicentre trial
Description
Design:
This is a retrospective study which aims to perform biomarker analyses on archived samples from patients with diffuse large B cell lymphoma (DLBCL) who have been treated on the R-CHOP 14 vs 21 multicentre trial. This will include all trial patients who have donated their tissue for research purpose and have tumour tissue available. This study will evaluate the incidence and the predictive/prognostic value of several biomarkers and will provide a valuable platform to complement ongoing translational studies on the R-CHOP14 vs 21 study cohort. Assessment of DNA methylation and mutations are currently the main focus of this study, but other biomarkers (e.g. DNA copy number changes, gene expression profiling and metabolites may be considered for analysis).
Treatment:
Tissue samples from patients enrolled on the R-CHOP 14 vs 21 multicentre trial between 2005 and 2009 were collected and stored at the Haematological Malignancy Diagnostic Service (HMDS) of St James’ University Hospital, Leeds for biomarker analyses. Suitable samples will be sent to the Royal Marsden NHS Foundation Trust for the purpose of this study. Molecular analyses include, but are not limited to, DNA methylation analyses, DNA sequencing, RNA expression analyses and immunohistochemistry. The molecular analyses data will be collected in an anonymised fashion and correlated to clinical outcome data.
Key inclusion/exclusion criteria:
DLBCL patients treated on the R-CHOP 14 vs 21 trial who consented for surplus tissue to be used in future ethically approved research.
Duration of recruitment:
N/A
Aim
To evaluate the prognostic value of tumour biomarkers in patients with DLBCL treated on the R-CHOP 14 vs 21 multicentre trial.